Avacta Therapeutics
  • About
  • Our Science
  • Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • About
    • About Avacta
    • Leadership
    • Scientific Resources
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Leadership
    • Scientific Resources
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
Home News Investors Page 5
filter by: view all | Blogs | Diagnostics | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics

Investors

26 Jun 2024

AGM Business Update

Investors
20 Jun 2024

Shaun Chilton is appointed Non-Executive Chairman of the Avacta Board of Directors

Investors
11 Jun 2024

Appointment of Nominated Adviser and Sole Broker

Investors
03 Jun 2024

Research & Development Spotlight Series – Episode 3

Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
31 May 2024

Posting of Annual Report and Notice of AGM

Investors
23 May 2024

Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta’s AVA6000 Phase 1 trial

Investors | Therapeutics
30 Apr 2024

Preliminary Results for the Year Ended 31 December 2023

Investors
30 Apr 2024

Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group

Investors
25 Apr 2024

Research and Development Spotlight Series – Episode 2

Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
23 Apr 2024

Block Listing Application to AIM

Investors

Posts navigation

Older posts
Newer posts
Avacta Therapeutics
  • Diagnostics
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Corporate Responsibility
  • Contact Us

Avacta Group plc

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

ICR Consilium
85 Gresham Street
London
EC2V 7NQ

 

Email

Twitter | Linkedin

©2025 Avacta Therapeutics. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok